Vitiligo: Mechanistic Insights Lead to Novel Treatments
Department of Dermatology; Graduate School of Biomedical Sciences, Immunology and Microbiology Program; Graduate School of Biomedical Sciences, MD/PhD Program; UMass Metabolic Network
Allergy and Immunology | Cellular and Molecular Physiology | Dermatology | Immune System Diseases | Skin and Connective Tissue Diseases
Vitiligo is an autoimmune disease of the skin characterized by patchy depigmentation. Current treatments are moderately effective at reversing disease by suppressing autoimmune inflammation in the skin and promoting the regeneration of melanocytes. Recent basic and translational research studies have significantly improved our understanding of disease pathogenesis, which is now leading to emerging treatment strategies based on targeted therapy. Here we discuss important clinical characteristics of vitiligo, current therapies, their limitations, advances in understanding disease pathogenesis, emerging targeted treatments, and strategies to optimize clinical trials to efficiently and effectively test these new treatments.
Rights and Permissions
Citation: J Allergy Clin Immunol. 2017 Sep;140(3):654-662. doi: 10.1016/j.jaci.2017.07.011. Epub 2017 Aug 1. Link to article on publisher's site
Frisoli, Michael L. and Harris, John E., "Vitiligo: Mechanistic Insights Lead to Novel Treatments" (2017). UMass Metabolic Network Publications. 117.